Effects of lexipafant (BB-882), a platelet activating factor receptor antagonist, on liver damage due to bile duct ligation in rats

Basit Öğe Kaydı
dc.contributor.authorOeztuerk, Hulya
dc.contributor.authorOeztuerk, Hayrettin
dc.contributor.authorDokucu, Ali Ihsan
dc.contributor.authorOtcu, Selcuk
dc.date.accessioned2024-04-24T17:33:42Z
dc.date.available2024-04-24T17:33:42Z
dc.date.issued2006
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground and study aims : Extrahepatic cholestasis is one of the main factors causing liver fibrosis. In this study, we aimed to evaluate the effects of lexipafant (BB-882), a platelet activating factor receptor antagonist, on liver damage in rats with bile duct ligation. Methods: A total of 30 male Sprague-Dawley rats weighing 160-190 g were used in this study. Group I (Sham-control, n = 10) rats were undergone laparotomy alone and bile duct was just dissected from the surrounding tissue. Group 2 rats (BDL/Untreated, n = 10) were subjected to bile duct ligation and no drug was applied. Group 3 rats (BDUBB-882, n = 10) received a daily dose of BB-882 intraperitoneally for 14 days after BDL. At the end of the two-week period, biochemical and histological evaluation was processed. Results : The mean serum bilirubin and liver enzymes level significantly decreased, and Superoxide dismutase, catalase and glutathione peroxidase values were significantly increased in BDL/BB-882 group when compared to BDUUntreated group. The histopathological score was significantly less in the BDUBB-882 group compared to the BDL/Untreated rats. In the BDL/BB-882 group was observed less fibrosis and neutrophil infiltration. Conclusions : These results suggest that BB-882 (lexipafant) may reduce the severity of the inflammatory response to liver injury produced by bile duct ligation in rats.en_US
dc.identifier.endpage202en_US
dc.identifier.issn1784-3227
dc.identifier.issue2en_US
dc.identifier.pmid16929615
dc.identifier.scopus2-s2.0-33747621139
dc.identifier.scopusqualityQ3
dc.identifier.startpage197en_US
dc.identifier.urihttps://hdl.handle.net/11468/20806
dc.identifier.volume69en_US
dc.identifier.wosWOS:000240612900003
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherUniv Catholique Louvain-Uclen_US
dc.relation.ispartofActa Gastro-Enterologica Belgica
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBile Duct Ligationen_US
dc.subjectBb-882en_US
dc.subjectLexipafanten_US
dc.subjectRaten_US
dc.titleEffects of lexipafant (BB-882), a platelet activating factor receptor antagonist, on liver damage due to bile duct ligation in ratsen_US
dc.titleEffects of lexipafant (BB-882), a platelet activating factor receptor antagonist, on liver damage due to bile duct ligation in rats
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu